Urine test improves non-invasive detection of prostate cancer

HHS announces initiative to improve breast cancer screening and early detection

HHS, through the recently announced Office of Women’s Health, announced taht it will be pursuing a collaboration with the Agency for Healthcare Research and Quality and DenseBreast-info.org to strengthen breast cancer screening, expand breast density education, and improve timely diagnostic follow-up, particularly for midlife women.

October 30, 2026

Vol.52 No.40

By Claire Marie Porter

Clinical Roundup

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

October 30, 2026

Vol.52 No.40

Drugs & Targets

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

FDA has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, including both BRCA and non-BRCA mutations.

October 30, 2026

Vol.52 No.40

In Brief

UIC receives $5.3 million NIH grant to study population genomic cancer screenings

Knowing your genetic risk for diseases like cancer can spur detection, prevention, and treatment. But some people don’t know or have access to their family’s medical history.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

Decipher Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term ADT, or androgen deprivation therapy, to dose-escalated radiation, providing both Level 1B1 prognostic and predictive evidence, according to a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial.

October 02, 2026

Vol.52 No.36

Urine test improves non-invasive detection of prostate cancer

YOU MAY BE INTERESTED IN

HHS announces initiative to improve breast cancer screening and early detection

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

UIC receives $5.3 million NIH grant to study population genomic cancer screenings

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login